US government's court battle begins over Gilead HIV drug patents
Jury selection begins today in a Delaware federal court for the lawsuit that kicked off in 2019 when the federal government sued Gilead, alleging that the sale of its HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP) infringes on government-owned patents.
While Truvada and Descovy were initially approved for the treatment of HIV back in 2004 and 2016, respectively, they were later approved in the preventive setting — Truvada in 2012 and Descovy in 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.